Form 4: Nuvectis Pharma Director Charles Mosseri Marlio Increases Stake with Open Market Purchase

Director Charles Mosseri Marlio reports purchasing 21,167 shares of Nuvectis Pharma at an average price of $8.11.

Summary

• On May 12, 2025, Charles Mosseri Marlio, a director of Nuvectis Pharma, Inc. purchased 21,167 shares of common stock at an average price of $8.11.
• The shares were acquired indirectly through Emerald Hill Ventures SARL SPF, of which Charles Mosseri Marlio is the beneficial owner.
• Following the transaction, Mr. Mosseri Marlio beneficially owns 2,942,761 shares of Nuvectis Pharma.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's purchase suggests confidence, but it's a single transaction and doesn't provide extensive insight into the company's overall health.

Positives

• The director's purchase could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, such as directors and officers, trade their company's stock. These filings provide transparency to the market regarding insider activity.

Stakeholder Impact

• The purchase may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Nuvectis Pharma, NVCT, Charles Mosseri Marlio, Emerald Hill Ventures, Beneficial Ownership, Form 4, Director, Share Purchase